Shift Towards Medicare Advantage Plans Anticipated Amid Rising PDP Premiums and Decreased Options | AMCP 2024
Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy at BluePeak Advisors, highlights the expected shift of Medicare beneficiaries towards Medicare Advantage Prescription Drug (MA-PD) plans.
Due to decreasing Prescription Drug Plan (PDP) options, rising PDP premiums and the additional benefits and risk management capabilities offered by MA-PD plans, there is an expected shift toward MA-PD plans, according to Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy, BluePeak Advisors.
“We're really not going to see how that membership shifts right until we get through open enrollment, but what I think we're going to see is a shift to MA-PDs because of the additional coordination of benefits,” Moore said. “MA-PDs have more avenues and mechanisms to spread out the increased financial liability and risk.”
Moore spoke today at AMCP Nexus 2024, held at the MGM Grand Conference Center in Las Vegas. She co-led a session today called, ‘CY 2025 Medicare Part D Redesign: A Medicare Odyssey.’
BluePeak Advisors is a healthcare consulting company that specializes in Medicare.
Addressing the Challenges of AI is Imperative | AMCP Nexus 2024
October 22nd 2024There is a need for strict policies regarding the use of AI in the managed care space, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
AI Benefits PBMs, Health Plans and Formulary Decision Making | AMCP Nexus 2024
October 21st 2024Health plans and PBMs are using AI to aggregate data, summarize information and enhance their formulary decision-making processes, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
Technology can help address the complexities of specialty medications by automating processes and enabling proactive interventions to ensure patients stay on their critical therapies, according to Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research.
Read More
How Technology Benefits Specialty Pharmacy | AMCP 2024
October 18th 2024Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research, explains how technology identifies at-risk patients, coordinates medication refills and more.
Read More
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
